Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system

Marco E Zamora,Eno-Obong Essien,Kartik Bhamidipati,Aditi Murthy,Jing Liu,Hyunjun Kim,Manthan N Patel,Jia Nong,Zhicheng Wang,Carolann Espy,Fatima Chaudhry,Laura T Ferguson,Sachchidananda Tiwari,Elizabeth Hood,Oscar A Marcos-Contreras,Serena Omo-Lamai,Tea Shuvaeva,Evguenia Arguiri,Jichuan Wu,Lubica Rauova,Mortimer Poncz,Maria C Basil,Edward Cantu,Joseph D Planer,Kara Spiller,Jarod Zepp,Vladimir Muzykantov,Jacob W Myerson,Jacob S Brenner

DOI: https://doi.org/10.1101/2024.06.07.597904

2024-06-10

Abstract:Nanomedicine has long pursued the goal of targeted delivery to specific organs and cell types but has not achieved this goal with the vast majority of targets. One rare example of success in this pursuit has been the 25+ years of studies targeting the lung endothelium using nanoparticles conjugated to antibodies against endothelial surface molecules. However, here we show that such 'endothelial-targeted nanocarriers' also effectively target the lung's numerous marginated neutrophils, which reside in the pulmonary capillaries and patrol for pathogens. We show that marginated neutrophils' uptake of many of these 'endothelial-targeted nanocarriers' is on par with endothelial uptake. This generalizes across diverse nanomaterials and targeting moieties and was even found with physicochemical lung tropism (i.e., without targeting moieties). Further, we observed this in ex vivo human lungs and in vivo healthy mice, with an increase in marginated neutrophil uptake of nanoparticles caused by local or distant inflammation. These findings have implications for nanomedicine development for lung diseases. These data also suggest that marginated neutrophils, especially in the lungs, should be considered a major part of the reticuloendothelial system (RES), with a special role in clearing nanoparticles that adhere to the lumenal surfaces of blood vessels.

Bioengineering

What problem does this paper attempt to address?

This paper discusses a long-standing challenge in nanomedicine, which is how to effectively deliver drugs to specific organs and cell types. The study focuses on successful cases of targeting pulmonary endothelial cells, which are the target of antibody-conjugated nanoparticles in the lungs. However, the authors found that these so-called "endothelium-targeted" nanocarriers are also effectively taken up by marginal neutrophils in the lungs, which reside in pulmonary capillaries and are responsible for patrolling and clearing pathogens.

The research shows that the uptake of various nanomaterials and targeted ligands by marginal neutrophils is comparable to or even higher than that by endothelial cells. This has been demonstrated in in vivo and in vitro experiments using both healthy and disease models, including human lung tissue. These findings have important implications for the development of nanomedicine for pulmonary diseases and raise new questions, such as the potential impact of nanocarriers on the function of marginal neutrophils, leading to unexpected side effects, or the possibility of utilizing this mechanism to control critical side effects.

Furthermore, the study suggests that marginal neutrophils should be considered as part of the reticuloendothelial system (RES), particularly in their role in clearing nanoparticles adhering to the vascular surface. Since marginal neutrophils are also present in other organs and diseases, this discovery may influence the understanding and application of the RES concept.

In summary, the paper attempts to address the question of whether nano drug delivery systems truly only target the intended endothelial cells or if there are other cell types involved that are not fully understood, and what this means for the practical efficacy and potential side effects of nanomedicine.